Abstract：
The development of the immune checkpoint inhibitors (ICI) is one of the most remarkable achievements in cancer therapy in recent years. However, their exponential use has led to an increase in immune-related adverse events (irAEs). Gastrointestinal and liver events encompass hepatitis, colitis and upper digestive tract symptoms accounting for the most common irAEs, with incidence rates varying from 2% to 40%, the latter in patients undergoing combined ICIs therapy. Based on the current scientific evidence derived from both randomized clinical trials and real-world studies, this statement document provides recommendations on the diagnosis, treatment and prognosis of the gastrointestinal and hepatic ICI-induced adverse events.
摘要：
免疫检查点抑制剂（ICI）的开发是近年来癌症治疗中最引人注目的成就之一。然而,它们的指数使用导致免疫相关不良事件(irAEs)增加.胃肠道和肝脏事件包括肝炎，结肠炎和上消化道症状占最常见的IRAE，发病率从2%到40%不等，后者在接受ICIs联合治疗的患者中。根据目前来自随机临床试验和现实世界研究的科学证据，这份声明文件提供了关于诊断的建议，胃肠道和肝脏ICI引起的不良事件的治疗和预后。
